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Background The prognostic impact of pulmonary arterial pressure (PAP)
remains controversial in aortic stenosis (AS) and few studies focused only on
patients with preserved left ventricular ejection fraction (LVEF). We therefore
aimed to investigate the impact of PAP, derived from our large catheterization
database, on survival in severe AS with preserved LVEF.
Methods and results Between 2000 and 2010, 749 patients (74±8y, 57%
of males) with preserved LVEF and severe AS without other valvular heart
disease underwent cardiac catheterization, including right heart hemody-
namic assessment. Pulmonary hypertension (PH) was defined as mean PAP
>25mmHg.
Systolic and mean PAP were 34.5±12 and 21.9±9mmHg, respectively.
Overall, 29% (n=215) of patients had PH, and these patients were signifi-
cantly older (p<0.0001), with lower LVEF (p<0.0001) and higher heart rate
(p=0.016) than those without PH. In addition, they more frequently had,
hypertension (p<0.0001), diabetes (p=0.001), coronary artery disease (CAD,
p<0.0001) and chronic pulmonary disease (p=0.043). Aortic valve replace-
ment (AVR) was performed in 91% of patients and 30-day mortality was
4.3%, significantly higher in patients with PH (7.7 vs. 3.4%, p=0.014). In
logistic regression analysis, after adjustment for age, gender, LVEF, CAD
and mean transaortic pressure gradient, mean PAP was an independent pre-
dictor of increased 30-day mortality (OR=1.06, 95% CI: 1.02-1.1, p=0.004).
Overall long-term survival was significantly reduced in patients with PH as
compared to those without PH (10-year survival: 41±8 vs. 61±3%,
p<0.0001). In multivariate analysis, after adjustment for all cofactors, PH
was an independent predictor of mortality (HR=1.5, 95% CI: 1.1-2.1,
p=0.037). 
Conclusion In patients with severe AS and preserved LVEF, PAP is an
independent predictor of both 30-day and long-term mortality. In order to
improve the prognosis of these patients, AVR could be considered before the
occurrence of severely elevated PAP.
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Background Early and late atrioventricular blocks (AVB) are frequent
during trans-aortic valve replacement (TAVR) leading to permanent pace-
maker (PPM) implantation. 
Whether His Bundle recording (HBR) during and after TAVR can predict
AVB remains a matter of debate.
Objective To correlate HV interval during and after TAVR with early and
late AVB occurrence. 
Methods Between January 2013 and December 2014, HBR was assessed
prospectively before balloon inflation (HV1), 15minutes after (HV2), and at
day 2 and 5 for Sapiens and CoreValve (HV3) in all pacemaker-free patients
undergoing TAVR. PPM was implanted when permanent AVB persisted over
day, or if paroxystic AVB occurred within the first 5 days or if HV3 >80ms.
Logistic regression was performed to assess if HVB could well predict early
(from day 1 to day 5) or late (from day 5 to day 30) AVB occurrence.
Results 86 patients aged of 85±8,2 years old, with a Euroscore of 15,3±9,3
and of whom 50(79%) were female were recruited. Corevalve was predomi-
nantly used (59(66%)). HV1, HV2 and HV3 were 56±9ms, 70±19ms and
63±14ms respectively. In total, 29 (34%) PPM were implanted before dis-
charge of which 18 (19,7%) for documented AV bloc, 8 for prolonged HV
interval and 3 for sick sinus syndrome. 12 patients (13,9%) showed AVB
during follow-up after discharge, all implanted for early AVB. There was no
AVB recorded in PPM for prolonged HV interval, programmed with a diag-
nostic atrio-ventricular conduction preservation algorithm. HV1 and HV2
were not associated with early AVB occurrence (p=0,79 and p=0,34 respec-
tively).
Prolonged HV1, HV2 or HV3 did not predict late AVB occurrence either
(p=0,54, p=0,90 and p=0,91 respectively).
Conclusion High degree AVB is a common finding after TAVR and can
occur late. Repeated HBR before and after TAVR did not show any signifi-
cant predictive value for early and delayed AVB. 
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Background and aim TAVI is increasingly used but few data exist on
long-term outcome. 
We analyzed 7-year outcome after TAVI and its predictive factors. 
Methods Between 2006 and 2011, 289 consecutive high-risk patients
(EuroScore 23±14%) underwent TAVI in our institution. Mean age was
82±9 years and 85% were in NYHA class III–IV. 
Results Procedural success was achieved in 265 pts (92%). At 30 days,
34 patients died (congestive heart failure in 14, peri-procedural death in 10
and septic shock in 10). We focused on the 255 patients discharged alive after
TAVI to analyze long-term outcome. Follow-up was complete in 100% of
patients. During a mean follow-up of 4.1±0.2 years, 139 patients died, half of
deaths being non-cardiac. 
Overall 7-year survival rate was 26±9%. We identified 5 preprocedural
predictive factors of late mortality in multivariate analysis: cancer (p=0.001),
diabetes under insulin therapy (p=0.02), NYHA class III-IV (p=0.03), atrial
fibrillation (p=0.04), higher creatinin level (p<0.0001) and 2 post-procedural
factors: higher systolic PAP (p=0.02) and arrhythmias (p=0.02). Whereas
conduction disorders are more frequent after TAVI (29% of cases in this
series) and may often lead to pace-maker implantation, only post-TAVI
arrhythmias (supraventricular in 32 patients or ventricular in 4) were predic-
tive of late mortality. Finally, in the 116 survivors, 70% were in NYHA class
I-II at last follow-up. 
Conclusions At 7-year follow-up after TAVI, the survival rate was 27%
and most patients have few or no symptoms. The predictive factors of late
mortality emphasized the weight of comorbidities. Particular awareness is
needed toward the occurrence of post-TAVI arrhythmias which identifies
high-risk patients.
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